anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Twenty-five percent of older adults experience significant osteoarthritis (OA)-related comorbid sleep disturbance. Insomnia is associated with substantial negative effects on function, mood, and medical resource utilization. Cognitive behavioral therapy for insomnia (CBT-I) is evidence based and has been shown to be efficacious in populations with a variety of comorbid conditions including OA-related chronic pain. However, in-person CBT interventions are unlikely to be widely deployable in healthcare systems. Telephone delivery has the advantage of giving patients access to personalized, efficacious CBT-I interventions from home, increasing generalizability, and outreach to minority, rural, and other underserved populations. Older (60+ yrs) primary care patients across Washington State will be screened for severe persistent OA-related insomnia and pain. Two hundred and seventy patients will be randomized to either CBT-I or an education only attention control (EOC). Each treatment will consist of six 20-30 minute telephone-based sessions over an eight week period. Pre-treatment, post-treatment (2 months and 12 month) assessments will include measures of sleep, pain, fatigue, mood, and quality of life. A cost effectiveness evaluation of the intervention will also be conducted. The proposed research will determine if telephone CBT-I improves OA insomnia and associated outcomes in a state-wide primary care population of older adults, and inform policy decisions about widespread dissemination of telephone CBT-I in this and related patient populations.
FIELD: veterinary science. SUBSTANCE: invention relates to the preparation used for correction of immune system disorders and prophylaxis and treatment of animals with infectious and invasion diseases being in mammals of all species. The preparation "Milon" is the organogermanium derivative of pyridinediol of the composition C 15 H 27 N 3 O 6 Ge. Pharmacological effect of the preparation involves the broad spectrum of activities: immunomodulation (as the main), antiviral, anthelmintic and antibacterial. EFFECT: enhanced effectiveness of the preparation. 4 cl, 2 tbl, 8 ex
Dry eye disease (DED) is a prevalent chronic eye disease characterized by an aberrant inflammatory response in ocular surface mucosa. The immunological alterations underlying DED remain largely unknown. In this study, we employed single-cell transcriptome sequencing of conjunctival tissue from environment-induced DED mice to investigate multicellular ecosystem and functional changes at different DED stages. Our results revealed an epithelial subtype with fibroblastic characteristics and pro-inflammatory effects emerging in the acute phase of DED. We also found that T helper (Th)1, Th17, and regulatory T cells (Treg) were the dominant clusters of differentiation (CD)4+ T-cell types involved in regulating immune responses and identified three distinct macrophage subtypes, with the CD72+CD11c+ subtype enhancing chronic inflammation. Furthermore, bulk transcriptome analysis of video display terminal-induced DED consistently suggested the presence of the pro-inflammatory epithelial subtype in human conjunctiva. Our findings have uncovered a DED-associated pro-inflammatory microenvironment in the conjunctiva, centered around epithelial cells, involving interactions with macrophages and CD4+ T cells, which deepens our understanding of ocular surface mucosal immune responses during DED progression.
BACKGROUND: High blood eosinophil count (BEC) is a useful biomarker for guiding inhaled corticosteroid therapy in patients with chronic obstructive pulmonary disease (COPD), yet its implications in a community setting remain underexplored. This study aimed to elucidate the clinical characteristics and outcomes of COPD patients with high BEC within the Chinese community.
METHODS: We obtained baseline and 2-year follow-up data from COPD patients (post-bronchodilator forced expiratory volume in 1 second/forced vital capacity <0.70) in the early COPD study. Patients with a BEC ≥300cells/μL were classified as the high BEC group. We assessed differences in the clinical characteristics and outcomes between high and low BEC patients. Subgroup analyses were conducted on COPD patients without a history of corticosteroid use or asthma.
RESULTS: Of the 897 COPD patients, 205 (22.9%) had high BEC. At baseline, high BEC patients exhibited a higher proportion of chronic respiratory symptoms, lower lung function, and more severe small airway dysfunction than low BEC patients. Over the 2-year period, high BEC patients experienced a significantly higher risk of acute exacerbations (relative risk: 1.28, 95% confidence interval: 1.09-1.49; P=0.002), even after adjusting for confounders. No significant difference was observed in lung function decline rates. The subgroup analysis yielded consistent results.
CONCLUSIONS: COPD patients with high BEC in a Chinese community exhibited poorer health status, more severe small airway dysfunction, and a higher risk of exacerbations. Future research should explore the pathological mechanisms underlying the poorer prognosis in patients with high BEC.
Frontline healthcare workers are at high risk of SARS (severe acute respiratory syndrome) CoV-2 (COVID-19) infection. Personal protective equipment (PPE), such as an N95 respirator (N95), is essential for prevention of COVID-19 among HCWs. N95s can prevent aerosolized transmission of viral particles and reduce COVID-19 among HCWs, helping to reduce infection rates and preserve the workforce. Under normal circumstances, the CDC recommends that HCWs dispose of N95s after a single patient encounter. However, during critical PPE shortages such as those during the current COVID-19 pandemic, the CDC recommends N95 extended use (wearing the same N95 for multiple patient encounters) and re-use (storing an N95 between shifts for use over multiple shifts). N95 shortages have been widely reported during the COVID-19 pandemic and have forced HCWs to practice extended use and reuse of N95s. Despite the CDC's guidelines, there are limited data regarding the efficacy of N95s under conditions of extended use and reuse and existing studies have been conducted in laboratory settings rather than in the actual health care environment. (Bergman 2012; Vuma et al 2019). This has left health care workers, including emergency department (ED) providers on the front lines of the COVID-19 pandemic, without clear guidance regarding N95 conservation. Many have implemented various reuse and extended use policies out of necessity but with no empirical evidence of their safety and effectiveness.

The study team conducted a pilot cross-sectional study of 68 ED providers who wore either a 3M 1860 dome style N95 or a duckbill N951. 70.6% of duckbill N95 failed a standardized fit test with 3M bitter solution and a hood. Of the dome style , 27.5% failed a fit test. N95 failure was associated with increasing numbers of shifts used: There were 0/11 failures after 1 shift, 1/12 failures after 2 shifts, 3/13 failures after 3 shifts, and 10/15 failures after 4 or more shifts. Also, more donnings and doffings were associated with fit failure, with a median of 8 donning and doffings in the fit pass group and 15 donning and doffings in the fit failure group. This preliminary study had a number of limitations, including a small sample size, convenience sampling, and cross-sectional design, and so was unable to definitively identify the number of shifts or donnings/doffings for which N95s can be safely reused.

The investigators propose to conduct a prospective cohort study of 396 participants across 6 ED sites to estimate the cumulative incidence of N95s when subjected to extended use and reuse in a clinical (emergency department) setting with fit test failure and contamination as the main endpoints. The investigators also seek to compare the fit test failure between varying types of HCWs wearing a number of N95 types. Additionally, the investigators will collect the N95s used in this study for additional analyses of at an outside laboratory measuring COVID-19 contamination levels and filtration efficiency.
Early-onset colorectal cancer (EOCRC) is defined as a diagnosis of colorectal cancer (CRC) in individuals younger than 50 years of age. While overall CRC rates in the United States (US) decreased between 2001 and 2018, EOCRC rates have increased. This research project aims to evaluate the feasibility and acceptability of Time-Restricted Eating (TRE), Mindfulness, or TRE combined with Mindfulness among young to middle-aged adults at risk of EOCRC. Forty-eight participants will be randomly assigned to one of four groups: TRE, Mindfulness, TRE and Mindfulness, or Control. Data on feasibility, adherence, and acceptability will be collected. Measures assessed at baseline and post-intervention will include body weight, body composition, dietary intake, physical activity, sleep behavior, circulating biomarkers, hair cortisol, and the gut microbiome. The effects of the intervention on the following will be examined: (1) acceptability and feasibility; (2) body weight, body composition, and adherence to TRE; (3) circulating metabolic, inflammation, and oxidative stress biomarkers; (4) intestinal inflammation; and (5) the gut microbiome. TRE, combined with Mindfulness, holds promise for stress reduction and weight management among individuals at risk of EOCRC. The results of this pilot study will inform the design and development of larger trials aimed at preventing risk factors associated with EOCRC.
The combination of irinotecan and temozolomide is well-tolerated and provides an active therapy option for heavily pre-treated patients with sarcoma. The toxicity profile and activity level suggest that this combination will provide a useful platform onto which novel compounds may be added. Pazopanib has been shown to demonstrate single-agent activity in sarcomas in the preclinical and clinical settings. Pazopanib has also been shown to have additive or synergistic effects in preclinical models of sarcomas when combined with cytotoxic chemotherapy. Pharmacokinetic studies of pazopanib and irinotecan as well as pharmacodynamic studies of pazopanib to assess anti-angiogenesis will be performed. Exploratory studies to assess non-invasive methods of monitoring tumor response \[circulating tumor DNA and functional imaging by positron emission tomography (PET)/magnetic resonance imaging (MRI) will be performed\].
PROBLEM TO BE SOLVED: To prepare a cosmetic containing a composite composition composed of a specific resin and powder subjected to specific treatment, and causing no agglomeration of the powder even in the presence of any electrolyte. SOLUTION: This cosmetic contains 0.1-30wt.% of a powder-resin composite composition comprising a hydrophilic resin and powder treated with a silane coupling agent-contg. monomer composition. The composition is prepared, preferably, by coating, with the hydrophilic resin, the powder treated with the monomer composition comprising a silane coupling agent and a monomer reactive to the silane coupling agent (pref. 1-acryloyloxy-3-trimethoxysilylpropane). The hydrophilic resin is pref. a (co)polymer containing at least one kind of monomer constituent selected from acrylic acid, methacrylic acid and vinyl alcohol. This cosmetic is used specifically as nailcolor, nailcoat, foundation, etc.
C-natriuretic peptide (CNP) has been shown to regulate proliferation of mouse and rat osteoblasts. Genetic deletion of CNP results in dwarfism. CNP effects on bone growth involve inhibition of MEK 1 and ERK 1/2 kinases mediated via the intracellular messenger cyclic GMP. Vessel dilator is another natriuretic peptide synthesized by the atrial natriuretic peptide gene whose biologic half-life is 12 times longer than CNP. Vessel dilator's biologic effects on proliferating cells are mediated via inhibiting MEK 1/2 and ERK 1/2 kinases via cyclic GMP. Vessel dilator was not studied previously on osteoblasts. CNP and vessel dilator were tested in dose-response studies enhanced human osteoblasts' proliferation, showing that vessel dilator has identical mechanisms of action to CNP but much longer biologic half-life and effects at lower concentrations. Vessel dilator exhibited therapeutic effect for use in human achondroplasia, short stature and osteoporosis by stimulating osteoblast proliferation.
Each capsule contained 275mg of maltodextrin. Capsules were similar to the saffron investigation product (chlorophyll capsules).
ETHNOPHARMACOLOGICAL RELEVANCE: Ginseng is a valuable herb in traditional Chinese medicine. Modern research has shown that it has various benefits, including tonifying vital energy, nourishing and strengthening the body, calming the mind, improving cognitive function, regulating fluids, and returning blood pressure, etc. Rg1 is a primary active component of ginseng. It protects hippocampal neurons, improves synaptic plasticity, enhances cognitive function, and boosts immunity. Furthermore, it exhibits anti-aging and anti-fatigue properties and holds great potential for preventing and managing neurodegenerative diseases (NDDs).
AIM OF THE STUDY: The objective of this study was to examine the role of Rg1 in treating chronic inflammatory NDDs and its molecular mechanisms.
MATERIALS AND METHODS: In vivo, we investigated the protective effects of Rg1 against chronic neuroinflammation and cognitive deficits in mice induced by 200 μg/kg lipopolysaccharide (LPS) for 21 days using behavioral tests, pathological sections, Western blot, qPCR and immunostaining. In vitro experiments involved the stimulation of HT22 cells with 10 μg/ml of LPS, verification of the therapeutic effect of Rg1, and elucidation of its potential mechanism of action using H2DCFDA staining, BODIPY™ 581/591 C11, JC-1 staining, Western blot, and immunostaining.
RESULTS: Firstly, it was found that Rg1 significantly improved chronic LPS-induced behavioral and cognitive dysfunction in mice. Further studies showed that Rg1 significantly attenuated LPS-induced neuronal damage by reducing levels of IL-6, IL-1β and ROS, and inhibiting AIM2 inflammasome. Furthermore, chronic LPS exposure induced the onset of neuronal ferroptosis by increasing the lipid peroxidation product MDA and regulating the ferroptosis-associated proteins Gpx4, xCT, FSP1, DMT1 and TfR, which were reversed by Rg1 treatment. Additionally, Rg1 was found to activate Nrf2 and its downstream antioxidant enzymes, such as HO1 and NQO1, both in vivo and in vitro. In vitro studies also showed that the Nrf2 inhibitor ML385 could inhibit the anti-inflammatory, antioxidant, and anti-ferroptosis effects of Rg1.
CONCLUSIONS: This study demonstrated that Rg1 administration ameliorated chronic LPS-induced cognitive deficits and neuronal ferroptosis in mice by inhibiting neuroinflammation and oxidative stress. The underlying mechanisms may be related to the inhibition of AIM2 inflammasome and activation of Nrf2 signaling. These findings provide valuable insights into the treatment of chronic neuroinflammation and associated NDDs.
Patient derived xenografts (PDX) are grown in mice. Organoids may generated from patient tumor(PDO) and PDX(PDxO). Organoids will be used for drug profiling. PDX, organoid establishment and drug profiling will occur while patient is undergoing preoperative chemo, surgery, radiation, and may extend into disease-free interval. Patients receive first line therapy in the metastatic setting per SOC or in separate clinical trial. Results of PDM drug profiling, tumor genomic, and circulating tumor DNA results will be returned to treating physician to inform 2nd line therapy. At progression on the first line therapy, the patient will begin new therapy as directed by the treating physician. Any subsequent therapy (aligned or unaligned with report recommendations) that a patient starts after the return of results will be deemed "informed".
The invention discloses a Chinese medicinal preparation for treating infantile upper respiratory tract infection and a preparation method thereof. The Chinese medicinal preparation comprises the following raw material medicaments: Indian buead, ephedra herb, kudzuvine root, white mustard seed, schizonepeta spike, cicada slough, platycodon root, astragalus, gypsum, mint, tangerine peel, divaricate saposhnikovia root, baical skullcap root and heartleaf houttuynia herb. For infants accompanied by sore throat and antiadoncus, watermelon frost and honeysuckle flower are added into the raw material medicaments; for infants accompanied by pyrexia and high fever, weeping forsythia, indigowoad root and gardenia are added into the raw material medicaments; for infants accompanied by poor appetite and indigestion, charred triplet and chicken's gizzard-membrane are added into the raw material medicaments; and for infants accompanied by cough with excessive phlegm, sessile stemona root and unibract fritillary bulb are added into the raw material medicaments. In the Chinese medicinal preparation, pungent warm is matched with acrid cold to dredge sweat pores and cleanse intrinsic heat; and the intrinsic heat is expelled by aiding with pivoting and elevating, and sour-sweet medicaments are subjected to compatibility to nourish yin, clear yingfen and remove the intrinsic heat. The infantile upper respiratory tract infection is caused by exogenous pathogens and seasonal pathogenic factors due to abnormal changes in temperature, and is easy to produce the intrinsic heat, so heat syndromes are common clinically, and quick defervescence is the main treatment aim. The Chinese medicinal preparation has the strong effects of resisting virus, allaying the fever, resisting inflammation and enhancing organism immunity.
Participants will receive MBK-01 capsules of intestinal microbiota coming from healthy donors. They will receive an initial dose of 4 capsules the first day, followed by a single daily capsule during 16 days. 3 months after the ending of the initial dose they will receive a maintenance dose, administered the same as the initial dose.
xCT (Slc7a11), the specific subunit of the cystine/glutamate antiporter system xc-, is present in the brain and on immune cells, where it is known to modulate behavior and inflammatory responses. In a variety of cancers -including pancreatic ductal adenocarcinoma (PDAC)-, xCT is upregulated by tumor cells to support their growth and spread. Therefore, we studied the impact of xCT deletion in pancreatic tumor cells (Panc02) and/or the host (xCT-/- mice) on tumor burden, inflammation, cachexia and mood disturbances. Deletion of xCT in the tumor strongly reduced tumor growth. Targeting xCT in the host and not the tumor resulted only in a partial reduction of tumor burden, while it did attenuate tumor-related systemic inflammation and prevented an increase in immunosuppressive regulatory T cells. The latter effect could be replicated by specific xCT deletion in immune cells. xCT deletion in the host or the tumor differentially modulated neuroinflammation. When mice were grafted with xCT-deleted tumor cells, hypothalamic inflammation was reduced and, accordingly, food intake improved. Tumor bearing xCT-/- mice showed a trend of reduced hippocampal neuroinflammation with less anxiety- and depressive-like behavior. Taken together, targeting xCT may have beneficial effects on pancreatic cancer-related comorbidities, beyond reducing tumor burden. The search for novel and specific xCT inhibitors is warranted as they may represent a holistic therapy in pancreatic cancer.
The invention discloses a multi-mode cross attention-based Alzheimer disease diagnosis method. The focus is to learn the relation among the multi-modal data by using a multi-modal interaction mechanism, and fuse the multi-modal data so as to realize the diagnosis of the Alzheimer disease. The invention designs a cerebrospinal fluid encoder and an image encoder based on serial cavity convolution to respectively learn cerebrospinal fluid characteristics and multi-scale image characteristics. And capturing the relation among different modal data by using a multi-modal interaction module based on a cross attention mechanism for the learned multi-modal characteristics, and carrying out multi-modal data fusion. In order to fuse the multi-modal features more effectively, a mixing loss function is proposed for reducing the heterogeneous differences between different modalities. The invention designs the Alzheimer disease diagnosis method based on the multi-mode cross attention network based on the advantage of deep learning and combines the characteristics of multi-mode data, and has wide application prospect in the aspects of multi-mode medical data fusion, auxiliary diagnosis and the like.
In vitro fertilization patients submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
Patients receive guadecitabine SC on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
FIELD: veterinary science. SUBSTANCE: antiparasitic paste has an anthelmintic agent and an insecticide agent from the group of avermectine and vehicle. Farmacin is used as an anthelmintic agent and cereals of groats crops flour - as a vehicle. Paste has the following ratio of components, wt. -%: farmacin 49-63, and flour of cereals and groats crops 37-51. Paste can be used against parascaricides, strongilates, oxyure, gastric gadflies and other parasites. EFFECT: enhanced effectiveness of paste. 3 tbl, 2 ex
The time interval required for the initial dosage to produce an effect may vary. Diuresis and saluresis usually begin within one hour and persist for 24 hours or longer. When a desired therapeutic effect has been obtained, it may be advisable to reduce the dose if possible. The daily dose depends on the severity of the patient's condition, sodium intake, and responsiveness. A decision to change the daily dose should be based on the results of thorough clinical and laboratory evaluations. If antihypertensive drugs or diuretics are given concurrently with metolazone tablets more careful dosage adjustment may be necessary. For patients who tend to experience paroxysmal nocturnal dyspnea, it may be advisable to employ a larger dose to ensure prolongation of diuresis and saluresis for a full 24-hour period.
Fathers of very low birth weight preterm infants, i.e. gestational age from 22 0/7 to 31 6/7 weeks of gestation and with a birth weight below 1500 g.